Seelos Therapeutics Inc (SEEL)

[Bryce Harper]

Isn't it true that the FDA must act on the resubmission within 6 months only because the focus is on curing the deficiencies?

If Apricus has an improved formulation to present in the resubmission package, is the FDA still obligated to act within 6 months?

I think we can agree that the only NDA submission to the FDA so far was many years ago -- so any new data supporting a 7 day shelf life has not yet been submitted.

If they submit that data along with the data curing the deficiencies, does the 6 month evaluation deadline still apply?